China Oncology ›› 2023, Vol. 33 ›› Issue (5): 460-468.doi: 10.19401/j.cnki.1007-3639.2023.05.006
• Article • Previous Articles Next Articles
ZUO Xueliang1,2(), CHEN Zhiqiang3, DONG Runyu1, WANG Zhixiong1, CAI Juan2,4()
Received:
2022-10-26
Revised:
2023-03-02
Online:
2023-05-30
Published:
2023-06-16
Contact:
CAI Juan
CLC Number:
ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan. The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor[J]. China Oncology, 2023, 33(5): 460-468.
Tab. 1
Correlation between LDHA expression and clinicopathological features of gastric cancer patients"
Characteristic | LDHA low expression | LDHA high expression | χ2 value | P value |
---|---|---|---|---|
Gender | 0.021 | 0.886 | ||
Female | 6 | 4 | ||
Male | 23 | 17 | ||
Age/year | 0.618 | 0.432 | ||
<60 | 8 | 8 | ||
≥60 | 21 | 13 | ||
Tumor location | 0.019 | 0.890 | ||
Down | 16 | 12 | ||
Upper/middle | 13 | 9 | ||
ECOG performance score | 0.069 | 0.793 | ||
0-1 | 19 | 13 | ||
≥2 | 10 | 8 | ||
HER2 expression | 0.114 | 0.735 | ||
Negative | 27 | 19 | ||
Positive | 2 | 2 | ||
Metastasis sites | 0.618 | 0.432 | ||
≤2 | 21 | 13 | ||
>2 | 8 | 8 | ||
PD-L1 CPS | 1.439 | 0.230 | ||
≥5 | 10 | 4 | ||
<5 | 19 | 17 | ||
PD-1 inhibitor response | ||||
PD | 5 | 15 | 16.811 | <0.001 |
SD | 7 | 4 | ||
PR | 17 | 2 |
Tab. 2
Correlation between the efficacy of PD-1 inhibitor and clinicopathological features of gastric cancer patients"
Characteristic | Responder | Non-responder | χ2 value | P value |
---|---|---|---|---|
Gender | 0.764 | 0.382 | ||
Female | 5 | 5 | ||
Male | 14 | 26 | ||
Age/year | 3.701 | 0.054 | ||
<60 | 3 | 13 | ||
≥60 | 16 | 18 | ||
Tumor location | 2.401 | 0.121 | ||
Down | 8 | 20 | ||
Upper/middle | 11 | 11 | ||
ECOG performance score | 0.496 | 0.481 | ||
0-1 | 11 | 21 | ||
≥2 | 8 | 10 | ||
HER2 expression | 0.312 | 0.577 | ||
Negative | 18 | 28 | ||
Positive | 1 | 3 | ||
Metastasis sites | 3.701 | 0.054 | ||
≤2 | 16 | 18 | ||
>2 | 3 | 13 | ||
Immunotherapy line | 7.371 | 0.007 | ||
First-line | 7 | 2 | ||
Second-line and above | 12 | 29 | ||
PD-L1 CPS | 13.585 | <0.001 | ||
≥5 | 11 | 3 | ||
<5 | 8 | 28 | ||
LDHA expression | 12.462 | <0.001 | ||
Low | 17 | 12 | ||
High | 2 | 19 |
Fig. 1
LDHA expression is negatively correlated with the efficacy of PD-1 inhibitor in gastric cancer A: Representative IHC photographs of LDHA expression in tumor tissues from responders and non-responders. B: IHC scores of LDHA in tumor tissues from responders and non-responders. ***: P<0.001, compared with responder."
Fig. 2
ROC curve analyses of LDHA, PD-L1 and the combination of LDHA and PD-L1 in predicting the efficacy of PD-1 inhibitor in gastric cancer patients A: ROC curve of LDHA in predicting the efficacy of PD-1 inhibitor in gastric cancer patients; B: ROC curve of PD-L1 in predicting the efficacy of PD-1 inhibitor in gastric cancer patients; C: ROC curve of the combination of LDHA and PD-L1 in predicting the efficacy of PD-1 inhibitor in gastric cancer patients."
Fig. 3
Kaplan-Meier curve analyses of LDHA, PD-L1, the combination of LDHA and PD-L1 in predicting the OS of gastric cancer patients treated with PD-1 inhibitor A: Kaplan-Meier curve analysis of the correlation between LDHA expression and the OS of gastric cancer patients treated with PD-1 inhibitor; B: Kaplan-Meier curve analysis of the correlation between PD-L1 expression and the OS of gastric cancer patients treated with PD-1 inhibitor;C: Kaplan-Meier survival curves showing the effect of the combination of LDHA and PD-L1 on OS of gastric cancer patients treated with PD-1 inhibitor."
Fig. 4
Kaplan-Meier curve analyses of LDHA, PD-L1, the combination of LDHA and PD-L1 in predicting the PFS of gastric cancer patients treated with PD-1 inhibitor A: Kaplan-Meier curve analysis of the correlation between LDHA expression and the PFS of gastric cancer patients treated with PD-1 inhibitor; B: Kaplan-Meier curve analysis of the correlation between PD-L1 expression and the PFS of gastric cancer patients treated with PD-1 inhibitor; C: Kaplan-Meier survival curves showing the effect of the combination of LDHA and PD-L1 on PFS of gastric cancer patients treated with PD-1 inhibitor."
Tab. 4
Univariate analysis of OS and PFS of gastric cancer patients treated with PD-1 inhibitor"
Characteristic | OS | PFS | ||
---|---|---|---|---|
Log-rank | P value | Log-rank | P value | |
Gender (male vs female) | 0.085 | 0.770 | 0.060 | 0.806 |
Age (≥60 years vs <60 years) | 1.914 | 0.167 | 3.063 | 0.080 |
Tumor location (upper/middle vs down) | 1.034 | 0.309 | 0.847 | 0.357 |
ECOG performance score (≥2 vs <2) | 1.302 | 0.254 | 0.894 | 0.344 |
HER2 expression (positive vs negative) | 0.173 | 0.677 | 0.079 | 0.778 |
Metastasis sites (>2 vs ≤2) | 5.195 | 0.023 | 5.744 | 0.017 |
Immunotherapy line (first vs second and above) | 1.994 | 0.158 | 2.597 | 0.107 |
PD-L1 CPS (<5 vs ≥5) | 9.334 | 0.002 | 9.004 | 0.003 |
LDHA expression (high vs low) | 7.265 | 0.007 | 14.913 | <0.001 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] |
BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249.
doi: 10.1146/annurev-pathol-042020-042741 pmid: 33197221 |
[3] |
JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137 |
[4] |
KANG Y K, CHEN L T, RYU M H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 234-247.
doi: 10.1016/S1470-2045(21)00692-6 |
[5] |
SHITARA K, VAN CUTSEM E, BANG Y J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580.
doi: 10.1001/jamaoncol.2020.3370 |
[6] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648.
doi: S0140-6736(20)31288-5 pmid: 32861308 |
[7] |
LIU Y, GUO J Z, LIU Y, et al. Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth[J]. Nat Commun, 2018, 9(1): 4429.
doi: 10.1038/s41467-018-06841-7 pmid: 30356100 |
[8] |
SUN X R, SUN Z, ZHU Z, et al. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients[J]. PLoS One, 2014, 9(3): e91068.
doi: 10.1371/journal.pone.0091068 |
[9] |
GONG Y, JI P, YANG Y S, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets[J]. Cell Metab, 2021, 33(1): 51-64.e9.
doi: 10.1016/j.cmet.2020.10.012 pmid: 33181091 |
[10] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022. |
Guidelines Working Committee of the Chinese Clinical Oncology Society. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of gastric cancer 2022[M]. Beijing: People’s Health Publishing House, 2022. | |
[11] |
DEY P, KIMMELMAN A C, DEPINHO R A. Metabolic codependencies in the tumor microenvironment[J]. Cancer Discov, 2021, 11(5): 1067-1081.
doi: 10.1158/2159-8290.CD-20-1211 pmid: 33504580 |
[12] |
MARTÍNEZ-REYES I, CHANDEL N S. Cancer metabolism: looking forward[J]. Nat Rev Cancer, 2021, 21(10): 669-680.
doi: 10.1038/s41568-021-00378-6 |
[13] |
LI X Y, WENES M, ROMERO P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(7): 425-441.
doi: 10.1038/s41571-019-0203-7 pmid: 30914826 |
[14] |
VAUPEL P, SCHMIDBERGER H, MAYER A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression[J]. Int J Radiat Biol, 2019, 95(7): 912-919.
doi: 10.1080/09553002.2019.1589653 pmid: 30822194 |
[15] |
MA E H, VERWAY M J, JOHNSON R M, et al. Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8+ T cells[J]. Immunity, 2019, 51(5): 856-870.e5.
doi: 10.1016/j.immuni.2019.09.003 |
[16] |
KAYMAK I, WILLIAMS K S, CANTOR J R, et al. Immunometabolic interplay in the tumor microenvironment[J]. Cancer Cell, 2021, 39(1): 28-37.
doi: 10.1016/j.ccell.2020.09.004 pmid: 33125860 |
[17] |
JIANG W N, QIAO L, ZUO D, et al. Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer[J]. Ann Transl Med, 2021, 9(4): 358.
doi: 10.21037/atm-21-295 pmid: 33708985 |
[18] |
BRAND A, SINGER K, KOEHL G E, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells[J]. Cell Metab, 2016, 24(5): 657-671.
doi: S1550-4131(16)30427-2 pmid: 27641098 |
[19] |
ZHANG A K, XU Y Z, XU H S, et al. Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17[J]. Theranostics, 2021, 11(8): 3839-3852.
doi: 10.7150/thno.53749 pmid: 33664865 |
[20] |
MIZRAHI J, PANT S. Immunotherapy in gastrointestinal malignancies[J]. Adv Exp Med Biol, 2020, 1244: 93-106.
doi: 10.1007/978-3-030-41008-7_5 pmid: 32301012 |
[21] |
CHAO J, FUCHS C S, SHITARA K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials[J]. JAMA Oncol, 2021, 7(6): 895-902.
doi: 10.1001/jamaoncol.2021.0275 pmid: 33792646 |
[22] |
WAGNER N B, FORSCHNER A, LEITER U, et al. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies[J]. Br J Cancer, 2018, 119(3): 339-346.
doi: 10.1038/s41416-018-0167-x |
[23] |
DAHER S, LAWRENCE Y R, DUDNIK E, et al. Nivolumab in non-small cell lung cancer: real world long-term survival results and blood-based efficacy biomarkers[J]. Front Oncol, 2021, 11: 625668.
doi: 10.3389/fonc.2021.625668 |
[24] |
QIAO T Y, XIONG Y L, FENG Y B, et al. Inhibition of LDH-a by oxamate enhances the efficacy of anti-PD-1 treatment in an NSCLC humanized mouse model[J]. Front Oncol, 2021, 11: 632364.
doi: 10.3389/fonc.2021.632364 |
[25] |
ZHANG Y X, ZHAO Y Y, SHEN J Z, et al. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy[J]. Nano Lett, 2019, 19(5): 2774-2783.
doi: 10.1021/acs.nanolett.8b04296 |
[26] | FUCHS C S, DOI T, JANG R W, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013. |
[27] |
BANG Y J, KANG Y K, CATENACCI D V, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase Ⅱ nonrandomized KEYNOTE-059 study[J]. Gastric Cancer, 2019, 22(4): 828-837.
doi: 10.1007/s10120-018-00909-5 |
[1] | YANG Wenxiao, GUO Linwei, LING Hong, HU Xin. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy [J]. China Oncology, 2023, 33(5): 484-498. |
[2] | Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association . Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [J]. China Oncology, 2023, 33(5): 527-548. |
[3] | JIANG Jinling, ZHOU Chenfei, WANG Chao, ZHAO Liqin, WU Junwei, ZHANG Jun. Advanced progress in research and diagnosis of gastric cancer in 2022 [J]. China Oncology, 2023, 33(4): 303-314. |
[4] | TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022 [J]. China Oncology, 2023, 33(3): 191-200. |
[5] | SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022 [J]. China Oncology, 2023, 33(3): 218-227. |
[6] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[7] | CHEN Yuguang, SUN Xiao, BI Zhao, QIU Pengfei, DUAN Baowei, FAN Qingda, WANG Yongsheng. Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation [J]. China Oncology, 2023, 33(2): 142-151. |
[8] | CHEN Yingyao, CHU Xiangling, YU Xin, SU Chunxia. Advances in models predicting efficacy of immune checkpoint inhibitors [J]. China Oncology, 2023, 33(1): 61-70. |
[9] | GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021 [J]. China Oncology, 2022, 32(9): 772-778. |
[10] | YU Hang, LIU Wensheng, ZHANG Ning, LIU Haikuan, CHEN Luohai, YAO Wang, FAN Wenzhe, LI Jiaping, CHEN Jie, WANG Yu. The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis [J]. China Oncology, 2022, 32(9): 794-799. |
[11] | ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei. Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma [J]. China Oncology, 2022, 32(9): 807-817. |
[12] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[13] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[14] | XU Yuchen, CHENG Leilei, WANG Yan, LIN Jinyi, CHEN Jiahui, CHEN Yifan, ZHOU Yuhong, LIU Tianshu, GE Junbo. Predictive value of sST2 level in immune-related adverse events [J]. China Oncology, 2022, 32(8): 712-718. |
[15] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd